Nuclear Medicine: Imaging With Radioactive Tracers
Nuclear medicine is a specialized branch of medical imaging that uses small amounts of radioactive material — called radiotracers or radiopharmaceuticals — to evaluate organ function and detect disease at the molecular level. Unlike structural imaging modalities such as CT or MRI, nuclear medicine captures physiologic activity, making it particularly valuable for oncology staging, cardiac stress assessment, and thyroid evaluation. This page covers the definition and scope of nuclear medicine, the mechanism by which tracers produce diagnostic images, the clinical scenarios in which it is ordered, and the boundaries that distinguish it from adjacent imaging modalities.
Definition and scope
Nuclear medicine imaging produces functional maps of the body by detecting gamma radiation emitted from tracers that have been introduced into the body — most often by intravenous injection, but also by inhalation or oral ingestion. The U.S. Nuclear Regulatory Commission (NRC) regulates the medical use of radioactive materials under 10 CFR Part 35, which governs training requirements, authorized user designations, and radiation safety programs for clinical sites. The U.S. Food and Drug Administration (FDA) regulates the radiopharmaceuticals themselves as drugs under the Federal Food, Drug, and Cosmetic Act.
The scope of nuclear medicine spans two broad functional domains:
- Diagnostic nuclear medicine: includes single-photon emission computed tomography (SPECT), planar scintigraphy, and positron emission tomography (PET). These techniques image tracer distribution to assess metabolic activity, perfusion, or receptor binding.
- Therapeutic nuclear medicine (radionuclide therapy): uses higher-activity radiopharmaceuticals to treat disease, as in radioactive iodine (I-131) ablation of thyroid tissue or lutetium-177 DOTATATE therapy for neuroendocrine tumors (approved by the FDA in 2018 under the brand name Lutathera).
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) publishes procedural standards and appropriate-use criteria that guide clinical implementation across both domains.
How it works
The diagnostic process in nuclear medicine follows a structured sequence:
- Tracer selection: A radiopharmaceutical is chosen based on the organ system or pathology of interest. Fluorodeoxyglucose (FDG), a glucose analogue labeled with fluorine-18, is the most widely used PET tracer because malignant cells and inflamed tissues preferentially accumulate glucose.
- Administration: The tracer is delivered by injection, inhalation, or ingestion, depending on the target organ. An FDG PET scan requires a minimum 4-hour fast prior to injection to suppress physiologic glucose competition.
- Uptake period: The body is allowed a defined interval — typically 45 to 90 minutes for FDG PET — for the tracer to distribute and localize in target tissues.
- Image acquisition: A gamma camera (for SPECT or planar imaging) or a PET scanner detects photons emitted by the radiotracer. PET scanners detect 511-keV annihilation photons produced when positrons from the tracer encounter electrons in tissue.
- Image reconstruction and fusion: Raw emission data are reconstructed into tomographic slices. Most clinical systems are hybrid units — PET/CT or SPECT/CT — that fuse functional tracer maps with anatomic CT data acquired in the same session, enabling precise lesion localization.
- Interpretation: A physician with subspecialty training in nuclear medicine reviews the images and correlates findings with the patient's clinical history and laboratory data.
The radiation dose delivered depends on the tracer and administered activity. The National Council on Radiation Protection and Measurements (NCRP) provides guidance on typical effective doses; a whole-body FDG PET/CT study delivers an effective dose in the range of approximately 7 to 14 millisieverts (mSv), with CT attenuation correction contributing the majority of dose in many protocols. For broader context on dose management across imaging modalities, radiation dose in medical imaging is addressed in depth elsewhere on this site.
Common scenarios
Nuclear medicine studies are ordered when functional or metabolic information is clinically necessary and cannot be obtained through anatomic imaging alone. The most frequently performed categories include:
- Oncologic staging and treatment response: Whole-body FDG PET/CT is standard in staging lung cancer, lymphoma, esophageal cancer, and melanoma. SNMMI and the American College of Radiology (ACR) Appropriateness Criteria both support FDG PET/CT as a first-line modality in these indications.
- Cardiac perfusion imaging: Myocardial perfusion SPECT (MPS) or rubidium-82 PET perfusion studies evaluate coronary artery disease by comparing rest and stress tracer uptake in myocardial segments.
- Thyroid evaluation: Iodine-123 (I-123) thyroid scans assess nodule function and differentiate autonomous nodules from suppressed parenchyma; I-131 is used both diagnostically and therapeutically for differentiated thyroid cancer.
- Bone scintigraphy: Technetium-99m (Tc-99m) methylene diphosphonate (MDP) bone scans detect skeletal metastases, stress fractures, and osteomyelitis by imaging osteoblastic activity.
- Pulmonary ventilation-perfusion (V/Q) scanning: Used as an alternative to CT pulmonary angiography for evaluating suspected pulmonary embolism, particularly in patients with contrast allergies or impaired renal function, or during imaging during pregnancy.
Decision boundaries
Understanding where nuclear medicine sits relative to other modalities is essential for appropriate imaging selection — a topic covered systematically in the regulatory context for radiology and in the broader radiology resource index.
Nuclear medicine vs. CT/MRI: CT and MRI depict anatomy with high spatial resolution; nuclear medicine depicts physiology with lower spatial resolution but unique functional specificity. A lung mass visible on CT requires PET to determine metabolic activity and nodal involvement. Conversely, brain MRI detects structural lesions with superior resolution to PET for most non-oncologic neurologic conditions.
SPECT vs. PET: Both are tomographic nuclear medicine techniques, but they differ in physics and performance:
| Feature | SPECT | PET |
|---|---|---|
| Tracer emission | Single gamma photon | Positron → two 511-keV photons |
| Spatial resolution | ~10–15 mm | ~4–6 mm |
| Common tracers | Tc-99m, I-123, Tl-201 | F-18 (FDG), Rb-82, Ga-68 |
| Primary applications | Cardiac perfusion, bone, thyroid | Oncology, neurology, cardiology |
| Scanner cost and availability | Widely available | Less available, higher cost |
When nuclear medicine is not the primary choice: Acute trauma workup, routine appendicitis evaluation, and soft-tissue musculoskeletal injury characterization are domains where CT, MRI, or ultrasound provide faster and more diagnostically specific information. The ACR Appropriateness Criteria, maintained at acr.org, provide evidence-based guidance on modality selection for over 230 clinical scenarios and are the reference standard used by radiologists and referring clinicians to navigate these boundaries.
Radiation safety oversight for nuclear medicine facilities in the United States is shared between the NRC and Agreement States — 39 states as of the NRC's published agreement state program records — which assume regulatory authority under formal agreements with the NRC. The NRC Agreement State Program governs this framework.
References
- U.S. Nuclear Regulatory Commission — Medical Use of Radioactive Materials (10 CFR Part 35)
- U.S. FDA — Radiopharmaceuticals
- Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- National Council on Radiation Protection and Measurements (NCRP)
- American College of Radiology — ACR Appropriateness Criteria
- NRC Agreement State Program
The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)